New drug combo targets Hard-to-Treat cancers
NCT ID NCT03968653
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 37 times
Summary
This study tested an experimental oral drug (Debio 0123) combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had worsened after prior platinum-based treatment. The goal was to find the safest dose and check for side effects and early signs of tumor shrinkage. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinica Universidad de Navarra
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Hospital Universitario Virgen de la Victoria
Málaga, 29010, Spain
-
Hospital Vall Hebrón, Unidad de Investigación en Terapia Molecular (UITM)
Barcelona, 08035, Spain
-
Instituto Valenciano de Oncologia
Valencia, 46009, Spain
-
Leiden University Medical Center, Dept. of Clinical Oncology
Leiden, 2333, Netherlands
-
Radboud university medical center
Nijmegen, 6525, Netherlands
-
University Medical Center Groningen
Groningen, 9713, Netherlands
Conditions
Explore the condition pages connected to this study.